FDA approves Lilly’s Onswik, a once-weekly basal insulin treatment for adults with type 2 diabetes
LLY•The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes. Lilly said its Onswik KwikPen will be available in the U.S. in 500 units/mL and 1,000 units/mL concentrations.
1. FDA approval
The U.S. Food and Drug Administration approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes.
2. U.S. availability
Lilly said the Onswik KwikPen will be available in the U.S. in 500 units/mL and 1,000 units/mL concentrations.
